Abilify Manufactured by Bristol Myers Squibb

Links shared publicly online about this topic

Bristol-Myers Extends Abilify Sales Pact - WSJ.com

feeds.wsjonline.com — “Bristol-Myers Squibb will sell the psychiatric drug Abilify into 2015 under a deal with Otsuka Pharmaceutical.View full resource at feeds.wsjonline.com

  • View Related
  • Share

Most Recently Shared on April 6, 2009 at 2:23 pm By:

News: UK's NICE wants more data on the effectiveness of Bristol-Myers Squibb's schizophrenia drug Abilify http://bit.ly/9Zrcsf - #health

reuters.com — “News: UK's NICE wants more data on the effectiveness of Bristol-Myers Squibb's schizophrenia drug Abilify http://bit.ly/9Zrcsf - #healthView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on September 10, 2010 at 3:45 am By:

hrana Hisham Rana, MD Doctor and Physician

News: UK's NICE wants more data on the effectiveness of Bristol-Myers Squibb's schizophrenia drug Abilify http://bit.ly/9Zrcsf - #health

1 year ago...

Abilify Treats Autism-Related Irritability

webmd.com — “The drug abilify (aripiprazole) may help ease the symptoms of irritability related to autism in children and adolescents, a study shows.View full resource at webmd.com

  • View Related
  • Share

Most Recently Shared on November 30, 2009 at 8:08 pm By:

Abilify approved for irritability associated with autistic disorder - MPR

empr.com — “The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for the treatment of irritability associated with autistic disorder in pediatric patients 6"17 years of age, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on November 23, 2009 at 3:41 pm By:

eMPR MPR Medical Publisher

MPR News: Abilify approved for irritability associated with autistic disorder: The FDA has approved Abilify (aripip... http://bit.ly/510cxX

2 years ago...

Abilify approved as adjunct for maintenance treatment of bipolar disorder - MPR

empr.com — “Bristol-Myers Squibb and Otsuka announced that Abilify (aripiprazole) has been approved by the FDA as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on February 22, 2011 at 8:04 pm By:

eMPR MPR Medical Publisher

MPR News: Abilify approved as adjunct for maintenance treatment of bipolar disorder: Bristol-Myers Squibb and Ot... http://bit.ly/ffWVy7

12 months ago...

FDA approves sNDA for pediatric autism drug ABILIFY

news-medical.net — “Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on November 21, 2009 at 9:29 am By:

Obesity_News News-Medical.Net Health News

Obesity News: FDA approves sNDA for pediatric autism drug ABILIFY: Bristol-Myers Squibb Company an.. http://twurl.nl/kl8lfe

2 years ago...

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

news-medical.net — “Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on December 20, 2010 at 6:38 pm By:

HIVAIDS_News News-Medical.Net Health News

HIV/AIDS News: Bristol-Myers Squibb, Oncolys complete license agreement for festinavir: Bristol-Myers Squibb Com... http://bit.ly/ggbWKS

1 year ago...

Quebec agrees reimbursement of ABILIFY for schizophrenia treatment in public drug plans

news-medical.net — “Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on October 27, 2010 at 8:46 am By:

NewsMedical News-Medical.Net Health News

Quebec agrees reimbursement of ABILIFY for schizophrenia treatment in public drug plans: Bristol-Myers Squibb Cana... http://bit.ly/bY3JVo

1 year ago...

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

medicalnewstoday.com — “(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug ApplView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on November 28, 2009 at 11:28 am By:

mnt_clinical MNT Clinical Trials Health News

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated.. http://bit.ly/51H21G

2 years ago...

Abilify approved as adjunct for maintenance treatment of bipolar disorder - ONA

oncologynurseadvisor.com — “Bristol-Myers Squibb and Otsuka announced that Abilify (aripiprazole) has been approved by the FDA as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on February 22, 2011 at 7:15 pm By:

U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

drugs.com — “Abilify (aripiprazole) is used to treat irritability associated with autistic disorder in pediatric patients. Includes Abilify side effects, interactions and indications.View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on November 24, 2009 at 12:10 am By:

drugscom Drugs.com Health Site

FDA Approves Abilify for Irritability Associated with Autistic Disorder in Pediatric Patients - http://bit.ly/62jJ8P

2 years ago...

FDA panel recommends change to label of Abilify - Related Stories - AAP SmartBrief

smartbrief.com — “An FDA panel unanimously concluded that the label of Bristol-Myers Squibb's antipsychotic Abilify for use in children lacks information on the risk of excessive weight gain. The panel advised Bristol-Myers to keep monitoring pediatric use of the drug and move data on its metabolic effect on childrenView full resource at smartbrief.com

  • View Related
  • Share

Most Recently Shared on December 11, 2009 at 6:07 am By:

FDA approves Abilify for treating autistic irritability - Related Stories - AAP SmartBrief

smartbrief.com — “The FDA approved Abilify for treating irritability in autistic children ages 6 to 17 years. Bristol-Myers Squibb said approval was based on data from two Phase III studies that showed Abilify, when compared with a placebo, significantly improved scores on the Irritability subscale of the Aberrant BeView full resource at smartbrief.com

  • View Related
  • Share

Most Recently Shared on November 24, 2009 at 2:24 am By:

songMD Clara Song Doctor, Pediatrician, and Physician

FDA approves Abilify for treating autistic irritability http://sbne.ws/r/3kvd

2 years ago...

Experts question long-term efficacy of Abilify for bipolar disorder - Related Stories - AANP SmartBrief

smartbrief.com — “Researchers cited a lack of evidence for the effectiveness of Otsuka Pharmaceutical and Bristol-Myers Squibb's Abilify as maintenance therapy for bipolar disorder. Only one randomized, double-blind clinical trial evaluated Abilify's long-term benefits, and that study had limitations, researchers no--View full resource at smartbrief.com

  • View Related
  • Share

Most Recently Shared on May 4, 2011 at 3:33 pm By:

napernurse Dawn McKinney, MS/RN Nurse

Experts question long-term efficacy of Abilify for bipolar disorder http://sbne.ws/r/7HyH #BPD #PSY #pharm #EBP #nurse

9 months ago...

ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or Valproate - Business Wire - Wire - BradentonHerald.com

bradenton.com — “Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. , announced today that the U.S. Food and Drug Administration (FDA) has approved ABILIFY ® (aripiprazole) as an adjunct to the mood stabilizers lithium or valproate for the maintenance treatment of Bipolar I Disorder.View full resource at bradenton.com

  • View Related
  • Share

Most Recently Shared on February 17, 2011 at 5:02 pm By:

PeterBrownPsy Peter H Brown Doctor and Psychologist

ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I ... http://bit.ly/fnyJ5i #bipolar

12 months ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Featuring the top 3 experts for this topic

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390